WO2005005467A3 - Compose adjuvant de l'immunite comportant une sequence adenivirale ef - Google Patents

Compose adjuvant de l'immunite comportant une sequence adenivirale ef Download PDF

Info

Publication number
WO2005005467A3
WO2005005467A3 PCT/FR2004/050308 FR2004050308W WO2005005467A3 WO 2005005467 A3 WO2005005467 A3 WO 2005005467A3 FR 2004050308 W FR2004050308 W FR 2004050308W WO 2005005467 A3 WO2005005467 A3 WO 2005005467A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
sequence
polypeptide
immune booster
novel immune
Prior art date
Application number
PCT/FR2004/050308
Other languages
English (en)
Other versions
WO2005005467A2 (fr
Inventor
Jean-Paul Briand
Pierre Boulanger
Saw See Boulanger
Valerie Frenkel
Jean-Gerard Guillet
Armelle Blondel
Renee Lengagne
Original Assignee
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Jean-Paul Briand
Pierre Boulanger
Saw See Boulanger
Valerie Frenkel
Jean-Gerard Guillet
Armelle Blondel
Renee Lengagne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Centre Nat Rech Scient, Jean-Paul Briand, Pierre Boulanger, Saw See Boulanger, Valerie Frenkel, Jean-Gerard Guillet, Armelle Blondel, Renee Lengagne filed Critical Inst Nat Sante Rech Med
Priority to EP04767869A priority Critical patent/EP1644489A2/fr
Priority to CA002531208A priority patent/CA2531208A1/fr
Publication of WO2005005467A2 publication Critical patent/WO2005005467A2/fr
Publication of WO2005005467A3 publication Critical patent/WO2005005467A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L’invention concerne un composé peptidique adjuvant de l’immunité consistant en : - un polypeptide (i) comprenant une séquence d’acides aminés de 30 acides aminés de longueur contenue dans le domaine « tête » de la protéine « fibre » de la capside d’un adénovirus, ladite séquence d’acides aminés comprenant l’enchaînement d’acides aminés formant la structure en double feuillet β désignée « EF » contenue dans ledit domaine « tête » ; ou - un peptide (ii) analogue dudit polypeptide (i) dont la séquence en acides aminés comporte, par rapport à la séquence dudit polypeptide (i), au moins une substitution ou au moins une délétion d’un acide aminé, ledit peptide analogue conservant ladite structure en double feuillet β désignée « EF ».
PCT/FR2004/050308 2003-07-04 2004-07-02 Compose adjuvant de l'immunite comportant une sequence adenivirale ef WO2005005467A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04767869A EP1644489A2 (fr) 2003-07-04 2004-07-02 Compose adjuvant de l'immunite comportant une sequence adenovirale ef
CA002531208A CA2531208A1 (fr) 2003-07-04 2004-07-02 Compose adjuvant de l'immunite comportant une sequence adenivirale ef

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0308239A FR2856928A1 (fr) 2003-07-04 2003-07-04 Nouveau compose adjuvant de l'immunite, compositions le contenant et procedes mettant en oeuvre ledit compose adjuvant
FR03/08239 2003-07-04

Publications (2)

Publication Number Publication Date
WO2005005467A2 WO2005005467A2 (fr) 2005-01-20
WO2005005467A3 true WO2005005467A3 (fr) 2005-05-06

Family

ID=33522797

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2004/050308 WO2005005467A2 (fr) 2003-07-04 2004-07-02 Compose adjuvant de l'immunite comportant une sequence adenivirale ef

Country Status (4)

Country Link
EP (1) EP1644489A2 (fr)
CA (1) CA2531208A1 (fr)
FR (1) FR2856928A1 (fr)
WO (1) WO2005005467A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023728A1 (fr) * 1996-11-27 1998-06-04 Ludwig Institute For Cancer Research Adjuvant cellulaire
US20010049357A1 (en) * 1999-12-03 2001-12-06 De Asit K. Use of Hsp27 as an anti-inflammatory agent
WO2001092299A2 (fr) * 2000-06-02 2001-12-06 Novartis Ag Particules d'adenovirus avec proteines de fibres mutagenisees
EP1209226A2 (fr) * 2000-11-07 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Maturation de cellules dendritiques grâce à la protéine de choc thermique 70 (hsp70) recombinante

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023728A1 (fr) * 1996-11-27 1998-06-04 Ludwig Institute For Cancer Research Adjuvant cellulaire
US20010049357A1 (en) * 1999-12-03 2001-12-06 De Asit K. Use of Hsp27 as an anti-inflammatory agent
WO2001092299A2 (fr) * 2000-06-02 2001-12-06 Novartis Ag Particules d'adenovirus avec proteines de fibres mutagenisees
EP1209226A2 (fr) * 2000-11-07 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Maturation de cellules dendritiques grâce à la protéine de choc thermique 70 (hsp70) recombinante

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GOXE B ET AL: "SIMPLIFIED METHOD TO GENERATE LARGE QUANTITIES OF DENDRITIC CELLS SUITABLE CLINICAL APPLICATIONS", IMMUNOLOGICAL INVESTIGATIONS, MARCEL DEKKER, NEW YORK, NY, US, vol. 29, no. 3, August 2000 (2000-08-01), pages 319 - 336, XP001022582, ISSN: 0882-0139 *
KIRBY I ET AL: "IDENTIFICATION OF CONTACT RESIDUES AND DEFINITION OF THE CAR-BINDING SITE OF ADENOVIRUS TYPE 5 FIBER PROTEIN", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 6, March 2000 (2000-03-01), pages 2804 - 2813, XP000985401, ISSN: 0022-538X *
MOLINIER-FRENKEL V, GAHERY-SEGARD H, MEHTALI M, LE BOULAIRE C, RIBAULT S, BOULANGER P, TURSZ T, GUILLET JG, FARACE F.: "Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T Lymphocytes.", J VIROL., vol. 74, no. 16, August 2000 (2000-08-01), pages 7678 - 7682, XP002277467 *
MOLINIER-FRENKEL V, LENGAGNE R, GADEN F, HONG SS, CHOPPIN J, GAHERY-SEGARD H, BOULANGER P, GUILLET JG: "Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response.", JOURNAL OF VIROLOGY, vol. 76, no. 1, 2002, pages 127 - 135, XP002277466 *
MOLINIER-FRENKEL V, PREVOST-BLONDEL A, HONG SS, LENGAGNE R, BOUDALY S, MAGNUSSON MK, BOULANGER P, GUILLET JG.: "The maturation of murine dendritic cells induced by human adenovirus is mediated by the fiber knob domain.", J BIOL CHEM., vol. 278, no. 39, 26 September 2003 (2003-09-26), pages 37175 - 37182, XP002277468 *
REA D ET AL: "Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 166, no. 8, 15 April 2001 (2001-04-15), pages 5236 - 5244, XP002192775, ISSN: 0022-1767 *
ROUARD H ET AL: "Adenoviral transduction of human 'clinical grade' immature dendritic cells enhances costimulatory molecule expression and T-cell stimulatory capacity", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 241, no. 1-2, 31 July 2000 (2000-07-31), pages 69 - 81, XP004213712, ISSN: 0022-1759 *

Also Published As

Publication number Publication date
FR2856928A1 (fr) 2005-01-07
WO2005005467A2 (fr) 2005-01-20
EP1644489A2 (fr) 2006-04-12
CA2531208A1 (fr) 2005-01-20

Similar Documents

Publication Publication Date Title
ES2505695T3 (es) Composiciones inmunógenas para Streptococcus pyogenes
IN2014CN02050A (fr)
AR047347A1 (es) Miembros de la familia cry9 de bacillus
PE20100253A1 (es) Mutantes de fgf21
DE60322188D1 (de) Zytokin (zcytor17-ligand)
WO2002032232A3 (fr) Hydrolysats proteiques
WO2007076162A3 (fr) Peptides antimicrobiens de cathelicidine
ATE390441T1 (de) Niedrigallergene proteinvarianten
WO2007091030A3 (fr) Sequences et compositions de peptides
WO1998004702A3 (fr) Proteines, notamment proteines membranaires, d'helicobacter pylori, leur preparation et utilisation
WO2007029262A3 (fr) Compositions et methodes d'utilisation de ces dernieres en vue de detecter des virus
WO2010007144A3 (fr) Nouvelles protéines de nétrine 4 mutées, fragments de celles-ci et leurs utilisations en tant que médicaments
EP1548107A4 (fr) Chromoproteine et fluoroproteines
WO2002008426A3 (fr) Proteine
WO2004035618A3 (fr) Acides nucleiques codant pour le facteur d'adhesion du streptocoque du groupe b, facteur d'adhesion du streptocoque du groupe b et autres utilisations correspondantes
CA2249180A1 (fr) Procedes de production microbienne recombinante de proteines de fusion bpi et de peptides derives de bpi
WO2010057242A3 (fr) Vaccin
EP1700913A4 (fr) Proteines fluorescentes
WO2003090667A3 (fr) Composition immunogene ou vaccinale non immunosuppressive, comprenant une proteine e7 mutee du virus hpv-16
WO2005023992A3 (fr) Compositions et procedes permettant d'inhiber l'infection par le virus de la maladie des points blancs
AU2002307510A1 (en) Cytokine protein family
WO2007058267A8 (fr) Proteine innovante et gene codant pour la proteine
WO2005005467A3 (fr) Compose adjuvant de l'immunite comportant une sequence adenivirale ef
EP1213354A3 (fr) Procédé de préparation de 4-halo-3-hydroxybutanoate optiquement actif
DK1913020T3 (da) Immunogene konstrukter

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2531208

Country of ref document: CA

Ref document number: 2004767869

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004767869

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004767869

Country of ref document: EP